File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Hemolytic uremic syndrome in metastatic adenocarcinoma of the prostate

TitleHemolytic uremic syndrome in metastatic adenocarcinoma of the prostate
Authors
KeywordsHemolytic uremic syndrome (HUS)
Prostate carcinoma
Issue Date2002
Citation
American Journal of Kidney Diseases, 2002, v. 40 n. 6, p. 1334-1336 How to Cite?
AbstractThe authors report 4 cases of hemolytic uremic syndrome (HUS) in association with metastatic adenocarcinoma of the prostate. All patients were treated with hemodialysis with or without plasma exchange. All made a good recovery. In one patient the diagnosis of prostatic adenocarcinoma was first made after presentation with HUS. The authors suggest that this condition may be more common than previously thought and, that in view of its good prognosis, may be a separate entity to chemotherapy-associated HUS in patients with cancer. It also is recommended that adult male patients presenting with unexplained HUS should have clinical assessment of their prostate and measurement of prostate specific antigen. © 2002 by the National Kidney Foundation, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/195529
ISSN
2023 Impact Factor: 9.4
2023 SCImago Journal Rankings: 3.096
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMungall, S-
dc.contributor.authorMathieson, P-
dc.date.accessioned2014-02-28T06:12:17Z-
dc.date.available2014-02-28T06:12:17Z-
dc.date.issued2002-
dc.identifier.citationAmerican Journal of Kidney Diseases, 2002, v. 40 n. 6, p. 1334-1336-
dc.identifier.issn0272-6386-
dc.identifier.urihttp://hdl.handle.net/10722/195529-
dc.description.abstractThe authors report 4 cases of hemolytic uremic syndrome (HUS) in association with metastatic adenocarcinoma of the prostate. All patients were treated with hemodialysis with or without plasma exchange. All made a good recovery. In one patient the diagnosis of prostatic adenocarcinoma was first made after presentation with HUS. The authors suggest that this condition may be more common than previously thought and, that in view of its good prognosis, may be a separate entity to chemotherapy-associated HUS in patients with cancer. It also is recommended that adult male patients presenting with unexplained HUS should have clinical assessment of their prostate and measurement of prostate specific antigen. © 2002 by the National Kidney Foundation, Inc.-
dc.languageeng-
dc.relation.ispartofAmerican Journal of Kidney Diseases-
dc.subjectHemolytic uremic syndrome (HUS)-
dc.subjectProstate carcinoma-
dc.titleHemolytic uremic syndrome in metastatic adenocarcinoma of the prostate-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1053/ajkd.2002.36929-
dc.identifier.pmid12460056-
dc.identifier.scopuseid_2-s2.0-0036894024-
dc.identifier.volume40-
dc.identifier.issue6-
dc.identifier.spage1334-
dc.identifier.epage1336-
dc.identifier.isiWOS:000179581900029-
dc.identifier.issnl0272-6386-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats